Please login to the form below

Not currently logged in
Email:
Password:

Novartis' Reclast for osteoporosis approved by FDA

Swiss pharmaceutical company Novartis has won FDA approval for its osteoposis drug, Reclast (zoledronic acid), for the treatment of women with postmenopausal osteoporosis.

Swiss pharmaceutical company Novartis has won FDA approval for its osteoposis drug, Reclast (zoledronic acid), for the treatment of women with postmenopausal osteoporosis.

Novartis added that the European Commission (EC) is also expected to give its approval for Reclast in Q4 2007, following the positive opinion of the Committee for Medicinal Products. Reclast is already sold in the US and the EU as a treatment for Paget's disease.

In a clinical study involving more than 7,700 women, Reclast reduced the risk of spine fracture by 70 per cent and hip fracture by 41 per cent, Novartis said in a statement. The drug is administered as a once yearly intravenous injection.

Reclast is already in clinical studies to test Reclast's efficacy in the treatment of male osteoporosis.

According to a Datamonitor report, the osteoporosis market is due for a major upheaval when market leader Fosamax (alendronate) loses its US patent. New market entrants provide further complexity to the competitive landscape but will also drive market growth over the next ten years.

Eli Lilly has launched two osteoporosis drugs, Evista (raloxifene) and Forteo (teriparatide). In 2006, Evista generated sales of USD 739, while Forteo generated revenue of USD 574m.

21st August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
emotive.

emotive. is an award-winning healthcare communications agency working with leading global and EMEA companies in life sciences including medical device...

Latest intelligence

NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE
NEW EU DATA PROTECTION REGULATION POISED TO CHANGE DATA PRIVACY LANDSCAPE The bold digital clock featured on the EUGDPR (EU General Data Protection Regulation)1 website indicates – to the second...
Health knowledge: Why is it so important?
Health knowledge plays an important role in population health, but by itself is rarely enough to prompt a change in the behaviours that cause the risks....
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively....

Infographics